M&A / Deals UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases pharminent May 4, 2026
M&A / Deals Coultreon banks $125M to support testing of former Galapagos immune drug pharminent April 28, 2026
Clinical Data Oruka surges as long-acting psoriasis drug shows early promise pharminent April 27, 2026
Commercial Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change pharminent April 23, 2026
M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies pharminent April 22, 2026
M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies pharminent April 22, 2026
Clinical Data BioAge says early data suggest ‘best-in-class’ potential for inflammation drug pharminent April 21, 2026
M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers pharminent April 15, 2026
M&A / Deals BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut pharminent April 15, 2026
Clinical Data Spyre drug for inflammatory bowel disease shows promise in early study pharminent April 13, 2026
Policy / Pricing AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies pharminent April 7, 2026
Clinical Data Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off pharminent April 7, 2026
Clinical Data Sanofi immune drug hopeful posts mixed results in mid-stage tests pharminent April 7, 2026
Regulatory FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries pharminent April 1, 2026
M&A / Deals Biogen, with $5.6B Apellis buy, builds out immunology offerings pharminent March 31, 2026
Clinical Data Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline pharminent March 30, 2026
Regulatory Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents pharminent March 27, 2026
M&A / Deals Novartis targets Xolair successor in buyout of startup Excellergy pharminent March 27, 2026
M&A / Deals Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases pharminent March 24, 2026
